Inhalation Sedatives Market Report 2026

The inhalation sedatives market size has grown strongly in recent years. It will grow from $2.43 billion in 2025 to $2.57 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to limited availability of inhalation sedatives, reliance on traditional general anesthesia, growing hospital and surgical center infrastructure, increasing awareness of conscious sedation, adoption of nitrous oxide in dental practices.

The inhalation sedatives market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to development of new inhalation anesthetic agents, expansion of ambulatory surgical services, rising adoption of sedation monitoring technologies, integration of AI-based anesthesia management, growing demand for pediatric and outpatient sedation procedures. Major trends in the forecast period include rising adoption of inhalation sedatives in pediatric and adult surgeries, increased use of nitrous oxide for dental analgesia and minor procedures, growth in outpatient and ambulatory surgical centers utilizing sedation, integration of sedation techniques in pain management and anxiety reduction, focus on safety protocols and monitoring standards during sedation.

The increasing level of healthcare expenditure is expected to drive the growth of the inhalation sedatives market in the coming years. Healthcare expenditure refers to the total financial resources allocated by individuals, organizations, or governments toward the prevention, treatment, and management of health conditions. Spending on healthcare continues to rise due to advances in medical technology, as new diagnostic tools, treatments, and innovative therapies are often associated with higher costs, contributing to overall growth in healthcare budgets. Higher healthcare expenditure supports greater use of inhalation sedatives by enabling an increase in surgical procedures, wider adoption of advanced anesthesia equipment, improved patient access to care, and enhanced research and development efforts aimed at producing safer and more effective sedatives. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering Medicare and Medicaid, healthcare spending in the United States rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. Therefore, rising healthcare expenditure is contributing significantly to the growth of the inhalation sedatives market.

The growing prevalence of respiratory diseases is also expected to support the expansion of the inhalation sedatives market in the future. Respiratory diseases are conditions that affect the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Inhalation sedatives are used in the management of respiratory disorders to achieve objectives such as reducing patient anxiety, enhancing comfort, facilitating medical and diagnostic procedures, and supporting improved breathing and overall respiratory function. For instance, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, the number of chronic obstructive pulmonary disease (COPD) cases is projected to increase by 112 million, reaching a total of 592 million cases by 2050, which would account for about 9.5% of the eligible population. Consequently, the rising burden of respiratory diseases is expected to drive demand for inhalation sedatives.

Major companies operating in the inhalation sedatives market are introducing innovative services, such as inhalation sedation services, to enhance patient comfort and care experiences. Inhalation sedation services involve the controlled administration of sedative gases to help minimize anxiety and discomfort during medical or dental procedures. For example, in November 2023, Platinum Dental Services, a Ghana-based dental services provider, launched an inhalation sedation service aimed at improving patient comfort through the inhalation of a carefully balanced mixture of sedative gases during dental treatments. This approach effectively reduces fear and anxiety associated with dental visits, making it particularly beneficial for both adults and children who may feel apprehensive about dental care. By creating a safe and controlled environment, inhalation sedation allows patients to remain calm, comfortable, and responsive throughout procedures, thereby enhancing the overall patient experience and encouraging greater utilization of essential dental services.

Major companies operating in the inhalation sedatives market are AbbVie Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Hikma Pharmaceuticals plc, Jiangsu Hengrui Medicine Co. Ltd., Lunan Pharmaceutical Group Co. Ltd., Piramal Enterprises Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Zydus Cadila Health Care Limited, Torrent Pharmaceuticals Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Ltd., Wockhardt Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Jubilant Life Sciences Limited.

North America was the largest region in the inhalation sedatives market in 2025. The regions covered in the inhalation sedatives market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhalation sedatives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the inhalation sedatives market by increasing costs for imported anesthetic gases, monitoring equipment, and delivery systems. Segments like nitrous oxide and sevoflurane are most affected, particularly in North America and Europe, which rely heavily on imports from Asia-Pacific regions. This has led to higher operational costs and slower adoption in outpatient and dental centers. On the positive side, tariffs have encouraged local production, development of cost-efficient alternatives, and innovation in anesthesia delivery technologies.

The inhalation sedatives market research report is one of a series of new reports that provides inhalation sedatives market statistics, including inhalation sedatives industry global market size, regional shares, competitors with a inhalation sedatives market share, detailed inhalation sedatives market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation sedatives industry. This inhalation sedatives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Inhalation sedatives are calming agents administered through a nasal mask. At higher doses, they can function as general anesthetics, sedatives, or treatments for sleep-related disorders. Inhalation sedation involves the continuous delivery of a tranquilizing agent via a nose mask. This method is also commonly known as “happy gas,” “laughing gas,” or “conscious sedation,” and the gas used is nitrous oxide.

The primary products in the inhalation sedatives market include sevoflurane, desflurane, isoflurane, and nitrous oxide. Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether that is used as an inhalational anesthetic for the induction and maintenance of general anesthesia. These sedatives are used for applications such as induction and maintenance and are utilized across sectors including hospitals, ambulatory surgical centers, and others.

The inhalation sedatives market consists of sales of halothane, fluticasone, budesonide, and ciclesonide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.